Blood Lipids and Leptin Levels in Patients with Ischemic Heart Disease and Concomitant Non-Alcoholic Fatty Liver Disease after Treatment with Atorvastatin by Sklyarov, Yevgen & Karpyshyn, Nataliya
Archive of Clinical Medicine 2016
Vol. 22, Issue 2, E2016212
DOI: 10.21802/acm.2016.2.12
Research Article
Blood Lipids and Leptin Levels in Patients with
Ischemic Heart Disease and Concomitant
Non-Alcoholic Fatty Liver Disease after Treatment
with Atorvastatin
Yevgen Sklyarov, Nataliya Karpyshyn*
Abstract
Non-alcoholic fatty liver disease which is regarded as an independent predictor of cardiovascular diseases plays a significant
role in the development of ischemic heart disease. In patients with verified ischemic heart disease, hyperleptinemia causes
hypertrophy of vascular smooth muscle cells, increases the synthesis of endothelial growth factor as well as the accumulation
of reactive oxygen species in the vascular wall and leads to elevated expression of endothelin-1, which is also an indicator of
its influence on vascular remodeling. Leptin is a predictor of a higher functional class of angina pectoris and heart rhythm
disorders; it may be used as an indirect marker of systemic inflammation as well. Pathogenic basis for ischemic heart disease
treatment is hypolipidemic therapy with statins as the medications of choice; in addition to basic hypolipidemic action, they
improve endothelial function increasing nitric oxide synthesis possessing anti-inflammatory, anti-ischemic, antiaggregatory,
antithrombotic and profibrinolytic action, as well as antioxidant and antiproliferative effects.
The objective of the research was to study changes in blood lipids and leptin levels in patients with ischemic heart disease
and concomitant non-alcoholic fatty liver disease after a course of atorvastatin.
Materials and methods. 54 patients with ischemic heart disease and concomitant non-alcoholic fatty liver disease were
examined; there were 26 individuals who did not take atorvastatin and 28 individuals taking atorvastatin at a dose of 40 mg
per day for 3 months. All the patients underwent anthropometry, determination of blood lipids, leptin and liver transaminase
levels, electrocardiography, echocardiography, ultrasound of the internal organs.
Results. A significant decrease in the average level of total cholesterol (p<0.01), concentration of low-density lipoproteins
(p<0.01) and leptin level (p<0.01) was detected in patients after 3 months of atorvastatin use. Moreover, there was detected
a direct correlation between leptin level and triglyceride concentration, leptin level and the body mass index, leptin level and
waist circumference, leptin level and hip circumference, as well as a high correlation between total cholesterol and low-density
lipoproteins, and total cholesterol and the body mass index.
Conclusions. The administration of atorvastatin to patients with ischemic heart disease and concomitant non-alcoholic fatty
liver disease at a dose of 40 mg per day improves the patients’ general condition and promotes a significant decrease in
the levels of pro-atherogenic fractions of blood lipids and leptin level, as well as promotes the reduction in risk factors for
comorbid pathology and prevents the occurrence of its complications.
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Problem statement and analysis of the
recent research
Non-alcoholic fatty liver disease (NAFLD) which is regarded
as an independent predictor of cardiovascular diseases plays
a significant role in the development of ischemic heart dis-
ease (IHD) [1, 3, 5]. In patients with IHD, the coexistence of
NAFLD significantly increases the signs of ischemia and the
incidence of ventricular rhythm disturbances, worsens the in-
dices of autonomic regulation of cardiac activity, slows down
their improvement and accelerates the atherosclerotic pro-
cess in the myocardium according to data of spiral computer
tomography [2, 8].
Numerous experimental and clinical investigations showed
that adipocyte hormones such as leptin, adiponectin and re-
sistin play an important role in the regulation of liver lipid
metabolism and NAFLD pathogenesis [7, 10]; however, hyper-
leptinemia is an independent risk factor for the development
of infarction and stroke [4].
In patients with verified IHD, hyperleptinemia causes hy-
pertrophy of vascular smooth muscle cells, increases the syn-
thesis of endothelial growth factor as well as the accumulation
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of reactive oxygen species in the vascular wall and leads to
elevated expression of endothelin-1, which is also an indica-
tor of its influence on vascular remodeling [9]. Leptin is a
predictor of a higher functional class of angina pectoris and
heart rhythm disorders; it may be used as an indirect marker
of systemic inflammation as well since the reduction in its
level implies a more frequent reduction in c-reactive protein
[6].
Pathogenic basis for IHD treatment is hypolipidemic ther-
apy. The medications of choice are statins which reduce
cholesterol synthesis in the liver by means of competitive in-
hibition of HMG-CoA reductase [12]. In addition to basic
hypolipidemic action, statins improve endothelial function
increasing nitric oxide synthesis possessing anti-inflammatory
(decreasing hs-CRP concentration, reducing secretion of interleukin-
6, tumor necrosis factor), anti-ischemic, antiaggregatory, an-
tithrombotic and profibrinolytic action, as well as antioxidant
and antiproliferative effects [13].
The objective of the research was to study changes in
blood lipids and leptin levels in patients with IHD and con-
comitant NAFLD after a course of atorvastatin.
1. Materials and methods
54 patients with ischemic heart disease and concomitant non-
alcoholic fatty liver disease were examined. They were di-
vided into 2 groups: Group I included 26 individuals who did
not take atorvastatin, Group II included 28 individuals taking
atorvastatin at a dose of 40 mg per day for 3 months.
All the patients underwent anthropometry, determination
of blood lipids, leptin and liver transaminase levels, electro-
cardiography, echocardiography, ultrasound of the internal
organs.
Anthropometric measurements of height and body weight
calculating the body mass index (BMI) (Quetelet index):
BMI=weight (kg)/height (m2) were performed in all the pa-
tients.
The diagnosis of IHD was made based on the results of
coronarography, past myocardial infarction or positive tread-
mill test.
According to the guidelines of the International Diabetes
Federation (2005), to diagnose abdominal obesity, the waist
circumference (WC) was measured at the level of the umbili-
cus and assessed using the criteria for men WC>94 cm and
women WC>80 cm.
Blood lipids were estimated based on the serum levels of
total cholesterol (TC), triglycerides (TG), low-density lipopro-
tein (LDL) cholesterol and high-density lipoprotein (HDL)
cholesterol. The activity of serum alanine transaminase (ALT)
and aspartate aminotransferase (AST) was determined using
standard methods. Serum leptin level was determined us-
ing enzyme immunoassay test by means of spectrophotometer
“Stat-fax 1200”, diagnostic set of reagents (DRG International,
USA), ELISA test (“sandwich test”).
Ultrasonography of the hepatobiliary system was per-
formed on an empty stomach using Philips HDI 1500 ul-
trasound machine with a 3.5 mHz scanning sensor. The fol-
lowing parameters were determined: the size of hepatic lobes,
hepatic parenchyma density, the degree of fatty infiltration
of the liver, the presence of fibrosis and the diameter of the
vena portae (VP). Fatty infiltration of the liver was diagnosed
in case of enlarged liver, diffuse homogeneous increase in its
echogenicity, distal shadowing and dilated vena portae.
The efficacy of prescribed treatment was evaluated before
and after the 3-week therapy using atorvastatin at a dose of
40 mg a day.
The obtained results were processed in Microsoft Excel
using the Student’s t-test and the Pearson correlation analysis.
2. Results and Discussion
Among the patients of Group I, there were 13 (50.0%) males
and 13 (50.0%) females. The average age was 59.9±2.13
years. Among the patients of Group II, there were 21 (75.0%)
males and 7 (25.0%) females. The average age was 58.8±1.15
years (Table 1). When assessing the anthropometric indices in
patients of Group I, the average BMI constituted 32.2±0.65
kg/m2, while in patients of Group II it was 30.4±0.77 kg/m2.
In patients of Group I, the average index of waist circum-
ference constituted 111.0±1.7 cm, hip circumference consti-
tuted 101.8±1.99 cm, waist-to-hip ratio was 1.1±0.02. In
patients of Group II, the average index of waist circumference
constituted 103.9±1.27 cm, hip circumference constituted
96.5±1.51cm, waist-to-hip ratio was 1.1±0.01.
The comparison of the anthropometric data in patients
with IHD and concomitant NAFLD did not reveal a reliable
difference in age and anthropometric indices between patients
who did not take atorvastatin and those taking atorvastatin,
which indicated homogeneity of sampling.
Dyslipidemia, hypercholesterolemia with several cases of
the increase in ALT and AST were observed in all patients
with the given comorbidity.
3 months after administration of atorvastatin in complex
therapy for IHD and stable angina with concomitant NAFLD
the improvement of general condition was observed in the
group of patients taking atorvastatin which was manifested as
a reduction in the complaints concerning the cardiovascular
system.
The comparison of blood lipids levels in patients of Group
I and Group II revealed a pronounced hypolipidemic effect
which was accompanied by a reliable decrease in the aver-
age level of cholesterol from 6.1±0.19 mmol/l to 4.30±0.16
mmol/l (p<0.01) and concentration of LDL cholesterol from
4.10±0.19 mmol/l to 2.30±0.17 mmol/l (p<0.01) in the group
of patients taking atorvastatin for 3 months (Table 2). At
the same time, reliable changes in TG (p>0.05) and HDL
cholesterol (p>0.05) levels were not detected. Thus, after
administration of atorvastatin, a distinct tendency toward the
reduction in the levels of cholesterol and LDL cholesterol
on the background of slight changes in the levels of HDL
cholesterol and TG was observed.
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Table 1. Distribution of patients by age and sex
Indices, unit of measurement Group I (n=26) Group II (n=28) Reliability of the difference, p
Age, years 59.9±2.13 58.8±1.15 >0.05
BMI, kg/m2 32.2±0.65 30.4±0.77 >0.05
Waist circumference, cm 111.0±1.7 103.9±1.27 <0.01
Hip circumference, cm 101.8±1.99 96.5±1.51 <0.05
Waist-to-hip ratio 1.1±0.02 1.1±0.01 >0.05
Note.
n – the number of patients in the group
Table 2. Blood lipids levels in patients with IHD and concomitant NAFLD who took and did not take atorvastatin (M±m)
Indices Group I (n=26) Group II (n=28) Reliability of difference, p
TC, mmol/l 6.1±0.19 4.30±0.16 <0.01
LDL cholesterol, mmol/l 1.1±0.04 1.20±0.04 >0.05
HDL cholesterol, mmol/l 4.10±0.19 2.30±0.17 <0.01
TG, mmol/l 1.9±0.12 1.7±0.16 >0.05
Note.
n – the number of patients in the group
The analysis of correlations in the group of patients taking
atorvastatin for 3 months revealed a high correlation between
cholesterol and LDL (r=0.90), cholesterol and BMI (r=0.40).
A positive correlation was observed between TG and LDL
(r=0.41), BMI and LDL (r=0.40).
On the background of long-term intake of atorvastatin
at a dose of 40 mg, the level leptin decreased significantly
from 37.8±4.76 ng/ml to 15.6±2.58 ng/ml indicating leptin-
reducing effect of this drug (Table 3). At the same time, a
significant reduction in ALT level after atorvastatin intake
(p<0.05) was detected, while AST level did not differ signifi-
cantly, although there was a tendency to its reduction.
The analysis of correlations detected a positive relation be-
tween leptin and TG levels (r=0.50), leptin level and the BMI
(r=0.57). The correlation was noticed between leptin level
and waist circumference (r=0.50), leptin level and hip circum-
ference (r=0.49) as well. Thus, the reduction in leptin level
after treatment with atorvastatin results in the reduction in TG
level, the BMI, hip and waist circumferences, respectively.
Thus, the obtained data showed a positive effect of ator-
vastatin on both pro-atherogenic modified fractions of blood
lipids and the inhibition of leptinemia; it reduces risk factors
for IHD and NAFLD development thereby preventing the
incidence of complications.
3. Conclusions
• The administration of atorvastatin to patients with IHD
and concomitant NAFLD at a dose of 40 mg per day
improves the patients’ general condition and promotes
a significant decrease in the levels of pro-atherogenic
fractions of blood lipids.
• The administration of atorvastatin to patients with IHD
and concomitant NAFLD at a dose of 40 mg per day
leads to a significant reduction in leptin level.
• The reduction in leptin level after intake of atorvas-
tatin in patients with IHD and NAFLD promotes the
improvement of the patients’ general condition as well
as the reduction in risk factors for comorbid pathology
and prevents the occurrence of its complications.
4. Prospects for further research
Prospects for further research are to study the effect of ator-
vastatin on dynamics of changes in adiponectin and resistin
levels in patients with IHD and concomitant NAFLD after
hypolipidemic therapy with atorvastatin.
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